Clinical trials: Minimal Disease, Residual
Ependymoma
Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
This is a phase II study evaluating the feasibility of concurrent carboplatin given with focal radiation therapy in children age 12 months to < 21 years with newly diagnosed localized ependymoma who have no or minimal residual…
- Trial name
- NCT01088035
- Testing
- Carboplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
This phase I trial studies the side effects and best dose of selinexor when given after stem cell transplant in treating patients with acute myeloid leukemia that is at intermediate or high risk of spreading or coming back…
- Conditions
- Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Trial name
- NCT02485535
- Testing
- Laboratory Biomarker Analysis, Selinexor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Cancer
WT1 for the Detection of Minimal Residual Disease
The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.
- Trial name
- NCT00179829
- Testing
- WT 1 Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Minimal Residual Disease, Donor Lymphocyte Infusion
MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse remains an important problem.
- Conditions
- Minimal Residual Disease, Donor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation, Relapse
- Trial name
- NCT02673008
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Nanfang Hospital, Southern Medical University
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
This is a phase I trial of an investigational drug called GNKG168 in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) who are in morphologic remission but are positive…
- Trial name
- NCT01743807
- Testing
- GNKG168
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
B-cell Acute Lymphoblastic Leukemia
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before…
- Trial name
- NCT03509961
- Testing
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Where
- 24 sites in United States
- Volunteers
- 95 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
Acute Lymphoblastic Leukemia, Pediatric
MRD Detection by NGS in Pediatric T-ALL
This retrospective analysis aims to investigate pediatric patients with T cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS).
- Trial name
- NCT06525116
- Testing
- MRD
- Where
- China
- Volunteers
- 148 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy to kill…
- Trial name
- NCT00002701
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- 71 sites in Austria, Belgium and 7 more
- Volunteers
- 750 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adult Acute Lymphocytic Leukemia
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for…
- Trial name
- NCT00198991
- Testing
- Cyclophosphamide, Dexamethasone, Vincristine
- Where
- Germany
- Volunteers
- 1,883 people
- Sponsor
- Goethe University
Acute Lymphoblastic Leukemia
New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia , also known as acute lymphocytic leukemia, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as lymphoblasts, causing damage and death by inhibiting…
- Trial name
- NCT03249636
- Testing
- Flow cytometric analysis
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
This investigator-initiated, prospective, single-arm, open-label, single-center clinical study aims to evaluate the efficacy and safety of Inaticabtagene autoleucel (Inati-cel;CNCT19)CD19 CAR-T theraphy in adults B-ALL that are…
- Trial name
- NCT06718244
- Testing
- single dose of Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Esophageal Adenocarcinoma, Gastric Cancer
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment.
- Conditions
- Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CIT-SEQ (NCT07660627)
- Testing
- NGS sequencing of mutations selected based on sequencing of primary tumors
- Where
- Czechia
- Volunteers
- 34 people
- Sponsor
- Masaryk Memorial Cancer Institute
Leukemia
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
To learn if MT-0169 is safe to give to patients with AML or T-ALL. The effects of this drug will also be studied.
- Trial name
- NCT06522373
- Testing
- MT-0169
- Sponsor
- M.D. Anderson Cancer Center
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This randomized phase II trial studies how well treosulfan and fludarabine phosphate, with or without total body irradiation before donor stem cell transplant works in treating patients with myelodysplastic syndrome or acute…
- Conditions
- Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Myelodysplastic Syndrome
- Trial name
- NCT01894477
- Testing
- Allogeneic Bone Marrow Transplantation, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia
LAL-BR/2001: Study Treatment to Low Risk ALL
The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease
- Trial name
- NCT00526175
- Testing
- Prednisone, Vincristine, Daunorubicin
- Where
- 25 sites in Spain
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation